Moreover, in the TAILOR trial, which compared docetaxel with erlotinib as a second‐line treatment in NSCLC without EGFR mutations in exons 19 and 21, docetaxel use was shown to benefit survival 23. This evidence concerns the gene EGFR and non-small cell lung carcinoma.